Brenda J Weigel

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. pmc Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies
    Brenda J Weigel
    Department of Pediatrics, Division of Hematology Oncology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA
    Am J Hematol 87:953-6. 2012
  2. ncbi request reprint A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Clin Cancer Res 13:1789-93. 2007
  3. ncbi request reprint Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Pediatric Hematology Oncology and Blood and Marrow Transplant, Minneapolis, MN 55455, USA
    Exp Hematol 34:1403-12. 2006
  4. pmc Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia
    Qing Zhou
    Masonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 116:2484-93. 2010
  5. ncbi request reprint CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma
    Brenda J Weigel
    University of Minnesota Cancer Center, Department of Pediatrics, Division of Pediatric Hematology, Minneapolis, Minnesota 55455, USA
    Clin Cancer Res 9:3105-14. 2003
  6. pmc Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD)
    Patricia A Taylor
    Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 110:3480-8. 2007
  7. ncbi request reprint A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells
    Martin G Sauer
    University of Minnesota Cancer Center and Department of Pediatrics, Minneapolis, Minnesota 55455, USA
    Cancer Res 64:3914-21. 2004
  8. pmc Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia
    Qing Zhou
    Department of Pediatrics, Division of Blood and Marrow Transplantation, Masonic Cancer Center, University of Minnesota, Twin Cities, Minneapolis, MN 55455, USA
    Blood 114:3793-802. 2009
  9. ncbi request reprint Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Pediatric Hematology Oncology and Blood and Marrow Transplant, Minneapolis 55455, USA
    Blood 100:4169-76. 2002
  10. ncbi request reprint The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result from the rapid and prolonged activation of antigen-specific CD8+ T cells in vivo
    Lisa A E Harmala
    Department of Laboratory Medicine and Pathology, Center for Immunology, Cancer Center, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    J Immunol 169:5622-9. 2002

Detail Information

Publications12

  1. pmc Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies
    Brenda J Weigel
    Department of Pediatrics, Division of Hematology Oncology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA
    Am J Hematol 87:953-6. 2012
    ..2 mg/m(2) twice weekly with evidence of sustained tolerability and clinical activity in hematologic malignancies. Systemic TLR agonists for the treatment of hematologic malignancies warrant further study...
  2. ncbi request reprint A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Clin Cancer Res 13:1789-93. 2007
    ..To determine the recommended phase 2 dose, dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the heat shock protein (Hsp) 90 inhibitor, 17-allylaminogeldanamycin (17-AAG)...
  3. ncbi request reprint Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Pediatric Hematology Oncology and Blood and Marrow Transplant, Minneapolis, MN 55455, USA
    Exp Hematol 34:1403-12. 2006
    ....
  4. pmc Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia
    Qing Zhou
    Masonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 116:2484-93. 2010
    ..PD-1/PD-L1 blockade coupled with Treg depletion represents an important new approach that can be readily translated into the clinic to improve the therapeutic efficacy of adoptive AML-reactive CTLs in advanced AML disease...
  5. ncbi request reprint CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma
    Brenda J Weigel
    University of Minnesota Cancer Center, Department of Pediatrics, Division of Pediatric Hematology, Minneapolis, Minnesota 55455, USA
    Clin Cancer Res 9:3105-14. 2003
    ..CpG was also administered in combination with the chemotherapeutic agents, cyclophosphamide (CY) and topotecan, or surgical resection...
  6. pmc Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD)
    Patricia A Taylor
    Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 110:3480-8. 2007
    ..Our data further define the mechanisms of action and provide insight as to the potential clinical uses of FTY in allogeneic bone marrow transplant recipients...
  7. ncbi request reprint A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells
    Martin G Sauer
    University of Minnesota Cancer Center and Department of Pediatrics, Minneapolis, Minnesota 55455, USA
    Cancer Res 64:3914-21. 2004
    ..This survival advantage was achieved with short-term expanded CTLs only. The site of treatment failure was mainly the central nervous system where no CTLs could be identified at AML sites...
  8. pmc Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia
    Qing Zhou
    Department of Pediatrics, Division of Blood and Marrow Transplantation, Masonic Cancer Center, University of Minnesota, Twin Cities, Minneapolis, MN 55455, USA
    Blood 114:3793-802. 2009
    ....
  9. ncbi request reprint Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Pediatric Hematology Oncology and Blood and Marrow Transplant, Minneapolis 55455, USA
    Blood 100:4169-76. 2002
    ..These data have important clinical implications and are the first to show that Flt3L-generated DCs can provide antitumor protection and that nontoxic agents such as CpGs and Flt3L may be useful in the clinical development of DC vaccines...
  10. ncbi request reprint The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result from the rapid and prolonged activation of antigen-specific CD8+ T cells in vivo
    Lisa A E Harmala
    Department of Laboratory Medicine and Pathology, Center for Immunology, Cancer Center, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    J Immunol 169:5622-9. 2002
    ..These studies demonstrate that the potent adjuvant effect of M. tuberculosis hsp70 results from the relatively complete, rapid, and durable activation of Ag-specific CD8(+) T cells...
  11. ncbi request reprint Osteosarcoma in the first decade of life
    Rajaram Nagarajan
    Department of Pediatrics, Division of Epidemiology and Clinical Research, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Med Pediatr Oncol 41:480-3. 2003
  12. ncbi request reprint Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents
    Angela R Smith
    Department of Pediatrics, Division of Pediatric Hematology Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    Pediatr Blood Cancer 45:857-60. 2005
    ..These results in our adolescent patients are promising, but there is a need for well-designed studies to determine the efficacy, dosing, and safety of aprepitant in children of all ages...